DGAP-News

Sangui BioTech International Inc.: SastoMed enters into sales agreement for Turkey; Granulox receives product approval in Kuwait

DGAP-News: Sangui BioTech International Inc. / Key word(s): Miscellaneous
Sangui BioTech International Inc.: SastoMed enters into sales agreement for
Turkey; Granulox receives product approval in Kuwait

21.12.2016 / 10:43
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Sangui BioTech:
- SastoMed enters into sales agreement for Turkey
- Firm purchase commitments agreed
- Granulox receives product approval in Kuwait


Witten - December 21, 2016

Following the successful integration of the sales regions Southeast Asia
and Russia in October this year, SastoMed GmbH, to which Sangui BioTech
GmbH has licensed the worldwide distribution rights for the wound spray
Granulox, has also entered into a sales partnership in Turkey. With SAF
Pharma Health Services S.A. (SAF), a powerful partner for the introduction
of Granulox in this important territory was won. As was already the case
with Zuellig Pharma for Southeast Asia and the MDP Group for Russia, it was
also possible to agree with SAF guaranteed minimum purchase commitments for
Turkey. In the course of the next five years, SAF will, in line with the
anticipated course of the approval and reimbursement procedure, obtain
annually increasing minimum volumes with a total volume in the high five-
digit range. "With Turkey a further, promising sales region with 78
million inhabitants could be awarded to an ambitious partner. The fact that
minimum quantities could be agreed again underscores the confidence of our
partners in the successful market launch of Granulox, "says Michael Sander,
Managing Director of SastoMed GmbH.


In December, the product approval procedure for Granulox in Kuweit was
successfully completed. The product approval is essential for a successful
distribution of Granulox. Granulox was therefore approved for the first
time in an Islamic state. "This approval demonstrates that the marketing of
Granulox is also possible in countries which, due to religious practices,
are actually concerned about products containing porcine ingredients.
Outstanding performance from clinical and health economical perspective has
convinced local authorities and helped overcome limitations. This is an
important precedent that supports our efforts in other Muslim countries
such as Indonesia, "says Michel Sander.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: [phone]
e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such forward-
looking statements. Unless required by law, the Company undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.


---------------------------------------------------------------------------

21.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

532201 21.12.2016